Related Experiment Video
Updated: Sep 30, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Sugemalimab: First Approval
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Sugemalimab, an anti-PD-L1 antibody, is approved in China for first-line treatment of advanced non-small cell lung cancer (NSCLC) with specific mutations. It is also being investigated for other cancers and stages of NSCLC.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Sugemalimab is a fully human IgG4 monoclonal antibody targeting PD-L1.
- It is developed for advanced solid tumors and lymphoma.
Purpose of the Study:
- To summarize the development milestones of sugemalimab.
- To highlight its first approval for first-line treatment of specific metastatic non-small cell lung cancer (NSCLC).
Main Methods:
- Review of clinical development and regulatory submissions for sugemalimab.
- Analysis of its efficacy in combination regimens for NSCLC.
Main Results:
- Sugemalimab received approval in China for first-line treatment of EGFR/ALK-negative metastatic NSCLC.
- Combination therapies with sugemalimab demonstrated efficacy in both non-squamous and squamous NSCLC.
Conclusions:
- Sugemalimab represents a significant advancement in NSCLC treatment.
- Ongoing studies are exploring its potential in other cancers and earlier stages of NSCLC.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
09:29Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
Published on: February 1, 2013
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Tumor Immunotherapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...